Part of the raison d’etre of #StockMarketWatch is to fill in the gaps left by the mainstream media.

By @ZaksTradersCafe

It may be the pandemic, it may be other factors, but it seems in many of the small cap situations where we have been waiting a long time for things to happen – they actually are. This has been illustrated of late at long income play Dukemount Capital (DKE) and at sexual health play Futura Medical (FUM).

The latest company to end what has been quite a frustrating log jam is Oxford Biodynamics (OBD). Here the biotechnology company developing precision medicine tests for personalized healthcare based on the EpiSwitch ® 3D genomics platform, launched its EpiSwitch® COVID-19 Severity Test (CST), in the wake of an expanded strategy announced on 15 December 2020. Indeed, the shares rose 36%, and may have risen even more if the juiciest part of the RNS had not been hidden away at the end: “OBD is also continuing work on other products and indications, including rheumatoid arthritis, ALS, lymphoma and prostate cancer [4-7]. OBD will launch its predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments [8,9] in 2021. This EpiSwitch® IO response test aims to help physicians stratify complete and partial responders to targeted medicines, enabling improved treatment options and outcomes.” A severity test not just covering COVID-19, would almost certainly be game changing for the medical world.

Edtech specialist Dev Clever (DEV) was not only at a fresh 52 week high off the back of another 4% share price rise to 39p, it was one of the most followed stocks of the session as the company announced it has formed a Business Advisory and Intelligence Group to be chaired by Lord McNicol of West Kilbride. The remit of this group is to support and provide advice to Dev Clever and its executives regarding the development and global rollout of its careers guidance platform, and to provide thought leadership in the progression of global careers ad, and to positively influence the development of careers policy across different countries.

Shares of tech investor Asimilar (ASLR) were up 13% to 45p as traders did the maths regarding its holding in Dev from 10p and the way that this accounts for half of its market cap – and whose value has not been fully factored in to date.

It would appear that for Pluto Digital Assets things are moving along at the company well before it even hits the stock market. Here the news for the company which counts Riverfort (RGO), Pires (PIRI) and Argo Blockchain (ARB) as shareholders is that NFT Master, Blake Finucane has been added to the Pluto team. Pluto said that Blake has an extensive pedigree in the cryptocurrency space having bought her first Bitcoin in 2014, and started studying NFTs – non fungible tokens, right at the inception of the ERC-721 standard in 2017.

NFTs are in focus in the wake of Twitter founder Jack Dorsey selling his first tweet for $2.9m this week. Interest in NFTs has led to sharp share price rises for NFT plays Coinsilium (COIN) and Upper Thames Holdings (UPPT) on the Aquis exchange this month.

While shares of Canadian Overseas Petroleum (COPL) may currently be temporarily suspended in the wake of the Atomic deal in the UK, it was noticeable that a TR1 was issued showing that RBC Dominion Securities was in on the shareholder register at 5.51%,

After announcing the clearing of a stock overhang and beefed up its institutional shareholder list last week, sustainable hydrogen company pioneering hydrogen production from waste plastic, Powerhouse Energy (PHE) announced an update on its progress in the UK and Poland. The Company said its priority is to ensure the first hydrogen facility using its DMG technology, based at Peel NRE’s Protos site, meets the target of being commissioned and operational by the end of Q1 2022.

The words “return to profitability” can be the sweetest thing investors are delivered in a RNS, and this is what was seen at global gaming group Webis (WEB) in last month’s update. Group amounts wagered were US$ 45.3 million, up 20% on prior year (2019: US$ 37.7 million). Gross profit also rose to US$ 2.67 million (2018: US$ 1.79 million), up 49% versus prior year. Perhaps most importantly the company said that there is significant interest in its USA licensed position and it plans to maximise this position. Shares of Webis were up 15%.

(The opinions expressed here are those of the author, a columnist for Share Talk.)

Source is a purely journalistic website – Zak Mir is a member of the National Union of Journalists. There is no intention here of providing financial advice. It is recommended you seek an independent professional opinion before deciding whether or not to take any action with regard to anything written here.

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.

Tags: , , , , , , , , , , ,